Why the study?
Do drug-eluting stents reduce restenosis and target lesion revascularization compared to bare-metal stents?
Do drug-eluting stents reduce restenosis and target lesion revascularization compared to bare-metal stents?
Drug-eluting stents offer a marked reduction in restenosis and target lesion revascularization compared to bare-metal stents.
Percutaneous transluminal coronary angioplasty (PTCA) was developed as a nonsurgical alternative to coronary artery bypass graft surgery (CABG). Its limitations led to the introduction of stents. The introduction of baremetal stents (EMS) virtually eliminated the acute complications of PTCA. Drug-eluting stents (DES) were developed to combat the neo-intimal hyperplasia; and a marked reduction in restenosis rate and target lesion revascularization (TLR) was obtained with their use as compared to BMS.
No takes yet. Share an insight, caveat, or question.
Kaul et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: